



## **NEWS RELEASE**

### **ANTARES PHARMA TO PARTICIPATE IN THE 2013 RBC CAPITAL MARKETS' HEALTHCARE CONFERENCE**

**EWING, NJ, February 20, 2013** -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Paul K. Wotton, Ph.D., President and Chief Executive Officer, will participate in the RBC Capital Markets' Healthcare Conference on Wednesday February 27, 2013 at 8:30 am Eastern Time.

A live webcast will be available via the "Investor Relations" page of the Antares website, [www.antarespharma.com](http://www.antarespharma.com). A replay of the webcast will also be archived on Antares' website for 90 days from the date of participation.

#### **About Antares Pharma**

Antares Pharma focuses on self-administered parenteral pharmaceutical products and topical gel-based medicines. The Company is developing OTREXUP™, a combination product for the delivery of methotrexate using Medi-Jet™ technology for the treatment of rheumatoid arthritis, poly-articular-course juvenile rheumatoid arthritis and moderate to severe psoriasis, as well as VIBEX™ QS T for testosterone replacement therapy. The Company's technology platforms also include Vision™ reusable needle-free injectors marketed as Tjet® and Zomajet® by Teva Pharmaceutical Industries, Ltd (Teva) and Ferring Pharmaceuticals (Ferring), respectively, as well as VIBEX™ disposable Medi-Jet™ and multi-dose pen injector systems. Antares Pharma has a multi-product deal with Teva that includes Tev-Tropin® human growth hormone (hGH), VIBEX™ epinephrine and several other products. Antares Pharma's partnership with Ferring includes Zomacton® hGH. In the U.S. Antares has received FDA approval for Gelnique 3%™, a treatment for overactive bladder that is marketed by Actavis. Elestrin® (estradiol gel) is FDA approved for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, and is marketed in the U.S. by Meda Pharma. Antares Pharma has two facilities in the U.S. The Parenteral Products Group located in Minneapolis, Minnesota directs the manufacturing and marketing of the Company's reusable needle-free injection devices and related disposables, and develops its disposable pressure-assisted Medi-Jet™ and pen injector systems. The Company's corporate office and Product Development Group is located in Ewing, New Jersey.

#### **Contact:**

Jack Howarth  
Vice President, Corporate Affairs  
609-359-3016  
[jhowarth@antarespharma.com](mailto:jhowarth@antarespharma.com)